Ropes & Gray LLP

Ropes & Gray LLP supports key life sciences businesses on transactional, regulatory, litigation, and enforcement matters at every stage of the product development cycle. The firm has a strong corporate and commercial practice, with work across licensing and agreement collaborations, capital markets transactions, and M&A, among others; the latter is evidenced by its representation of ImmunoGen in its $10.1bn sale to AbbVie, completed in February 2024. The team is experienced in IP matters, including Hatch-Waxman litigation and due diligence of patent portfolios, while also supporting emerging companies and working on novel digital health issues. The practice is headed by Washington DC’s Kellie Combs, who specializes in FDA regulatory matters as well as the Public Health Service Act, and commercial transactions and strategic investments expert Michael Beauvais, based in Boston. Other key individuals in the team include DC’s Gregory Levine, who advises clients on FDA regulation of pharmaceuticals, biotech, and medical devices, supporting the company’s regulatory expertise. Marc Rubenstein retired from the practice in early 2025.